Study S001349

A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Clinical Study Comparing the Efficacy and Safety of Semaglutide Injection With Ozempic ® in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With Metformin

ClinicalTrials.gov record

Registration

Registration: NCT06739044
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 494
Start: 2023-09-20
Primary completion: 2024-10-11
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:Ozempic®; DRUG:HDG1901
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in HbA1c from baseline [Week 32]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0050399	839-P: Efficacy and Safety of HDG1901 vs. Ozempic in Patients with Type 2 Diabetes (T2D)—A Randomized, Open-Label, Bioequivalence Phase 3 Trial Lixin Guo, Diabetes	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06739044